Price movement over the last 24 hours
Alcon AG vs DuPont de Nemours Inc — how do they compare? Alcon AG trades at $66.75 (market cap $32.69B), while DuPont de Nemours Inc trades at $135.36 (market cap $18.85B). The key difference: Alcon AG is the larger of the two by market cap, and DuPont de Nemours Inc pays the higher dividend (1.72%). Which is the better fit depends on your goals.
| ALC | DD | |
|---|---|---|
Market Cap | $32.69B | $18.85B |
Sector | Health | Basic Materials |
52-Week High | $92.22 | $154.59 |
52-Week Low | $62.02 | $87.72 |
Enterprise Value | $36.28B | $21.31B |
Dividend Yield | 0.54% | 1.72% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
DuPont (DD) trades at $139.61, down 0.21% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten estimates, including Q1 2026 EPS of $1.65 versus $1.44 expected, though revenue declined to $6.85B in 2025. The company executed a 3:1 reverse stock split in June 2026 and maintains dividend payments, highlighting financial restructuring efforts amid mixed segment performance.
The outlook is cautiously optimistic with a consensus price target of $227.20, implying significant upside, but risks include persistent net losses, weak Q3 guidance concerns, and macroeconomic pressures on industrial segments. Investment appeal hinges on margin improvement and successful portfolio repositioning.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →